Cargando…
Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer
SIMPLE SUMMARY: Using a first-principles approach, we demonstrate how standard-of-care therapies for bone metastatic prostate cancer (BMPCa) patients can be optimized with the use of routine measurements to significantly delay the evolution of resistant disease, potentially extending overall patient...
Autores principales: | Araujo, Arturo, Cook, Leah M., Frieling, Jeremy S., Tan, Winston, Copland, John A., Kohli, Manish, Gupta, Shilpa, Dhillon, Jasreman, Pow-Sang, Julio, Lynch, Conor C., Basanta, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915310/ https://www.ncbi.nlm.nih.gov/pubmed/33567529 http://dx.doi.org/10.3390/cancers13040677 |
Ejemplares similares
-
Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer
por: Cook, Leah M., et al.
Publicado: (2016) -
Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer
por: Warman, Pranav I., et al.
Publicado: (2018) -
Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer
por: McGuire, Jeremy J., et al.
Publicado: (2021) -
Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome
por: Kumar, Nagi B., et al.
Publicado: (2022) -
Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy
por: Frieling, Jeremy S., et al.
Publicado: (2019)